DE69729183D1 - Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen - Google Patents

Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen

Info

Publication number
DE69729183D1
DE69729183D1 DE69729183T DE69729183T DE69729183D1 DE 69729183 D1 DE69729183 D1 DE 69729183D1 DE 69729183 T DE69729183 T DE 69729183T DE 69729183 T DE69729183 T DE 69729183T DE 69729183 D1 DE69729183 D1 DE 69729183D1
Authority
DE
Germany
Prior art keywords
dihydrobenzofuranes
compounds useful
related compounds
flamming
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69729183T
Other languages
English (en)
Other versions
DE69729183T2 (de
Inventor
Ichih Wu
Michael Janusz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Application granted granted Critical
Publication of DE69729183D1 publication Critical patent/DE69729183D1/de
Publication of DE69729183T2 publication Critical patent/DE69729183T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/382-Pyrrolones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58One oxygen atom, e.g. butenolide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
DE69729183T 1996-02-01 1997-01-30 Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen Expired - Fee Related DE69729183T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/595,337 US5618835A (en) 1996-02-01 1996-02-01 Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
PCT/US1997/001314 WO1997028147A1 (en) 1996-02-01 1997-01-30 Dihydrobenzofuran and related compounds useful as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
DE69729183D1 true DE69729183D1 (de) 2004-06-24
DE69729183T2 DE69729183T2 (de) 2004-10-07

Family

ID=24382842

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69729183T Expired - Fee Related DE69729183T2 (de) 1996-02-01 1997-01-30 Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen

Country Status (15)

Country Link
US (1) US5618835A (de)
EP (1) EP0888323B1 (de)
JP (1) JP3095424B2 (de)
KR (1) KR100322402B1 (de)
CN (1) CN1125062C (de)
AT (1) ATE267187T1 (de)
AU (1) AU730262B2 (de)
BR (1) BR9707247A (de)
CA (1) CA2244203A1 (de)
DE (1) DE69729183T2 (de)
DK (1) DK0888323T3 (de)
ES (1) ES2221950T3 (de)
MX (1) MX9806250A (de)
NO (1) NO983530L (de)
WO (1) WO1997028147A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69838789T2 (de) * 1997-03-12 2008-10-30 Suzanne Cambridge de la Monte Verfahren zur behandlung oder prävention der alzheimerischen krankheit
US6281229B1 (en) * 1997-06-27 2001-08-28 Kaneka Corporation Heat shock factor activity inhibitors
TR200001121T2 (tr) 1997-10-24 2000-09-21 Shionogi & Co., Ltd. Antiromatizmal madde.
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
IL159296A0 (en) 2001-06-13 2004-06-01 Magnachem Int Lab Inc Lactone formulations and method of use
EP1554572B1 (de) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US8188145B2 (en) 2002-06-12 2012-05-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
EP1562930A4 (de) 2002-11-05 2008-12-10 Magnachem Int Lab Inc Formulierungen synthetischer lactone undanwendungsverfahren
US7767701B2 (en) * 2002-11-22 2010-08-03 Glaxosmithkline Llc Chemical compounds
EP3827747A1 (de) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharmainformatiksystem
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
EP2063905B1 (de) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Behandlungen von lebererkrankungen durch verabreichung von konjugaten aus rezeptor-assoziierten proteinen
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
MX2011004331A (es) 2008-10-24 2011-09-21 Magnachem Int Lab Inc Metodo para busqueda de compuestos que interactuan selectivamente con rad9.
DE112010000714B4 (de) 2009-01-27 2014-06-26 National University Corporation Nagoya University Membranspannungsmessvorrichtung
NZ616673A (en) 2009-02-20 2014-08-29 To Bbb Holding B V Glutathione-based drug delivery system
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019305B2 (ja) * 1976-07-02 1985-05-15 ウェルファイド株式会社 ジヒドロベンゾフラン誘導体
IT1093805B (it) * 1978-01-31 1985-07-26 Erba Carlo Spa Derivati del 2h-benzofuran-3-one e procedimento per la loro preparazione
US4470440A (en) * 1982-09-30 1984-09-11 Thor Harry A Impact producing tool
DE3777366D1 (de) * 1986-12-27 1992-04-16 Takeda Chemical Industries Ltd 2,3-dihydro-cumaron-derivate, ihre herstellung und verwendung.
US4849428A (en) * 1987-11-23 1989-07-18 The Procter & Gamble Company Cyclic anti-inflammatory derivatives of di-tert-butylphenol compounds, compositions and use
JP2855341B2 (ja) * 1988-06-10 1999-02-10 武田薬品工業株式会社 新規2―置換クマラン誘導体
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
FR2645537B1 (fr) * 1989-04-05 1994-03-04 Fabre Medicament Pierre Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique
US4975457A (en) * 1989-09-25 1990-12-04 Merck & Co., Inc. Trans 2,3-disubstituted-2,3-dihydro-5-hydroxy-benzofurans as inhibitors of leukotriene biosynthesis
KR920701190A (ko) * 1989-11-17 1992-08-11 나까야마 히사시 벤조푸란유도체, 그의 제조법 및 이를 유효성분으로 하는 의약
US5091533A (en) * 1990-03-12 1992-02-25 Merck Frosst Canada, Inc. 5-hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors
NZ237566A (en) * 1990-03-27 1994-03-25 Smithkline Beecham Corp Substituted amide and hydroxyamine derivatives and pharmaceutical compositions
WO1996003396A1 (en) * 1994-07-27 1996-02-08 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US5684002A (en) * 1994-09-07 1997-11-04 The Procter & Gamble Company Dihydorbenzofuran and related compounds useful as anti-inflammatory agents

Also Published As

Publication number Publication date
DE69729183T2 (de) 2004-10-07
ES2221950T3 (es) 2005-01-16
AU730262B2 (en) 2001-03-01
DK0888323T3 (da) 2004-08-09
WO1997028147A1 (en) 1997-08-07
MX9806250A (es) 1998-11-30
JPH11506121A (ja) 1999-06-02
BR9707247A (pt) 1999-07-20
KR100322402B1 (ko) 2002-05-09
KR19990082222A (ko) 1999-11-25
ATE267187T1 (de) 2004-06-15
CN1210530A (zh) 1999-03-10
EP0888323A1 (de) 1999-01-07
CN1125062C (zh) 2003-10-22
US5618835A (en) 1997-04-08
CA2244203A1 (en) 1997-08-07
EP0888323B1 (de) 2004-05-19
JP3095424B2 (ja) 2000-10-03
NO983530D0 (no) 1998-07-31
AU1843397A (en) 1997-08-22
NO983530L (no) 1998-09-30

Similar Documents

Publication Publication Date Title
DE69729183T2 (de) Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
DK0915898T3 (da) Krystalform I af clarithromycin
AP9901478A0 (en) Compounds for the treatment of ischemia.
PT902789E (pt) Derivados de androsteno
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
DK0759687T3 (da) Anvendelse af gelpræparater som bejdsemidler
DE69814135D1 (de) 7-substituierte chinazolin-2,4-dionen verwendbar als antibakterielle mittel
PT934065E (pt) Compostos farmaceuticos
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
DE59903759D1 (de) Ektoparasitizide mittel
DE69613395D1 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel
GB9907571D0 (en) Compounds
DE69514100D1 (de) Substituierte kondensierte und verbrückte bicyclische verbindungen als therapeutische mittel
DE69535697D1 (de) Dihydrobenzofurane und verwandte verbindungen als entzündungshemmende mittel
DE69230644D1 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents
ID21653A (id) Komposisi untuk pengobatan atau pencegahan pankreatitis yang mengandung turunan diarilalkana sebagai bahan aktif
BR9902081A (pt) Combinação de dofetilida e um bloqueador dos canais de cálcio
IT1255678B (it) Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee